Clinical Trial Update: Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety study evaluating RAD001 (everolimus) in patients with metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED